Cambridge Scientists Reverse Developmental Brake on Nerve Regeneration Using Human Brain-Spinal Cord Organoids

Researchers at the University of Cambridge engineered interconnected brain- and spinal-cord organoids from patient-derived stem cells. They identified a gene network that curtails axon extension after roughly day 150 of organoid development and demonstrated that pharmacological blockade of key regulators restores regrowth, with the hormone drug lynestrenol markedly enhancing the effect.

SciTechDaily

In 2021 Dr. András Lakatos’s team generated cerebral-cortex-like organoids. Building on that platform, they cultured separate brain and spinal-cord organoids, allowed axons to bridge a gap, and observed functional synaptic activity that triggered contractions in adjacent muscle cell clusters. The combined system remained viable for more than a year.

Cambridge Team Restores Nerve Fiber Growth in Lab Models

• Dr. András Lakatos, senior author, Department of Clinical Neurosciences, Cambridge

SciTechDaily

• George Gibbons, first author, Department of Clinical Neurosciences, Cambridge

Cambridge Team Restores Nerve Fiber Growth in Lab Models

• Co-authors: Tanja Fuchsberger, Mai Abdelgawad, Stefano L. Giandomenico, et al.

SciTechDaily

The work was funded by the UK Research and Innovation Medical Research Council and Spinal Research.

SciTechDaily

• Axon regrowth observed in organoids up to ? day 150, corresponding to mid-pregnancy in human development.

Cambridge Team Restores Nerve Fiber Growth in Lab Models

• After this point, regenerative ability declined sharply.

Cambridge Team Restores Nerve Fiber Growth in Lab Models

• Inhibition of the identified gene network reinstated long-fiber growth.

SciTechDaily

• Lynestrenol treatment produced a significant increase in axon extension compared with untreated controls (exact magnitude not disclosed).

SciTechDaily

The findings suggest a neuron-intrinsic barrier, separate from scar tissue or inflammation, limits recovery after spinal-cord injury, motor-neuron disease, and multiple sclerosis. Overcoming this barrier could complement existing strategies and broaden therapeutic options for conditions currently deemed irreversible.

SciTechDaily

The Cambridge team reports that the developmental block on axon growth is reversible in human neurons, offering a mechanistic target for future interventions. They emphasize that organoid models provide a more accurate representation of human neural biology than rodent systems, thereby narrowing the translational gap. Funding agencies highlighted the project’s potential to advance regenerative neuroscience and reduce reliance on animal models.

SciTechDaily

Authors caution that lynestrenol is not a definitive treatment and that the observed regrowth must be validated in vivo. The organoid platform, while human-specific, does not fully replicate the adult injury environment, and functional reconnection of brain-spinal pathways remains to be demonstrated.

SciTechDaily

No contradictory data appear in the sources. Gaps include: (1) lack of quantitative efficacy metrics for lynestrenol, (2) uncertainty in translating organoid day 150 to precise human gestational timing, and (3) unknown long-term safety of manipulating the identified gene network.

SciTechDaily

• “Neurons taken from less mature organoids regrew long fibers after injury, but those from more mature organoids showed a sharp drop in their ability to regrow. In other words, poor regeneration is built into human neurons as they mature in the central nervous system.” — George Gibbons, First Author, Department of Clinical Neurosciences, Cambridge

SciTechDaily

• “Lynestrenol itself may not be the answer to spinal cord repair, but it shows us that, in principle, it should be possible to directly target human neurons and regenerate their axons. Although we still need to show that this strategy will also help to re-establish appropriate connections between the brain and spinal cord cells, this gives us hope that one day we may be able to treat conditions previously thought untreatable.” — Dr. András Lakatos

SciTechDaily

• “Much of what we know about nerve regeneration comes from rodents, whose neurons behave differently from human neurons. Our sophisticated organoid models help bridge the knowledge gap from animal models to what we see in patients. They are also an important contribution to efforts to reduce the use of animals in research.” — Dr. András Lakatos

SciTechDaily

The team plans to (1) screen additional compounds that modulate the identified gene network, (2) test the most promising candidates in animal models of spinal-cord injury, and (3) evaluate functional recovery and safety before considering early-phase clinical trials.

SciTechDaily